4//SEC Filing
MISRA TUSHAR 4
Accession 0001104659-24-004550
CIK 0001442836other
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 5:21 PM ET
Size
18.6 KB
Accession
0001104659-24-004550
Insider Transaction Report
Form 4
MISRA TUSHAR
Chief Manufacturing Officer
Transactions
- Award
Stock Option (Right to Buy)
2024-01-15+187,500→ 187,500 totalExercise: $3.02Exp: 2034-01-14→ Common Stock (187,500 underlying) - Exercise/Conversion
Restricted Stock Unit
2024-01-14−1,458→ 2,916 total→ Common Stock (1,458 underlying) - Award
Restricted Stock Unit
2024-01-15+41,667→ 41,667 total→ Common Stock (41,667 underlying) - Sale
Common Stock
2024-01-16$2.71/sh−3,357$9,097→ 17,966 total - Exercise/Conversion
Common Stock
2024-01-13+7,083→ 19,865 total - Exercise/Conversion
Common Stock
2024-01-14+1,458→ 21,323 total - Exercise/Conversion
Restricted Stock Unit
2024-01-13−7,083→ 21,250 total→ Common Stock (7,083 underlying)
Footnotes (10)
- [F1]Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 13, 2023.
- [F10]The RSUs shall vest in equal annual installments over four years from the date of grant.
- [F2]Includes 1,275 shares of common stock acquired by the Reporting Person on December 15, 2023 through the Issuer's employee stock purchase plan.
- [F3]Represents shares of common stock received upon vesting of a portion of the RSUs awarded to the Reporting Person on January 14, 2022.
- [F4]Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
- [F5]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.70 to $2.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F6]Each RSU represents the contingent right to receive one share of common stock of the Issuer.
- [F7]25% of the total number of RSUs granted vested on January 13, 2024, and the remainder shall vest thereafter in equal annual installments over the next three years.
- [F8]25% of the total number of RSUs granted vested on January 14, 2024, and the remainder shall vest thereafter in equal annual installments over the next two years.
- [F9]The option shall vest in equal quarterly installments over four years from the date of grant.
Documents
Issuer
Mersana Therapeutics, Inc.
CIK 0001442836
Entity typeother
Related Parties
1- filerCIK 0001877233
Filing Metadata
- Form type
- 4
- Filed
- Jan 16, 7:00 PM ET
- Accepted
- Jan 17, 5:21 PM ET
- Size
- 18.6 KB